Beijing SL Pharmaceutical and its subsidiary, Beijing SL Lisheng Medical Technology Co., Ltd. are engaged in the production of tablets, recombinant products, small volume parenteral solution, lyophilized powder for injection, capsules, granules, and bulk drugs (salcatonin, didanosine, ktreotide, cytidine disodium triphosphate and naftopidil); and the production and sale of health food. Co.'s major products are Recombinant Human Granulocyte Colony Stimulating Factor Injection, Recombinant Human Interleudin-2 for Injection, Recombinant Human Interleukin-11 for Injection, Coenzyme Complex for Injection and others.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.